Is there a big difference between Qilu Pharmaceutical’s version of Nilotinib and the original drug?

Nilotinib (Nilotinib) produced by Qilu Pharmaceutical is a generic version of the original drug Dasanib (Tasigna, Novartis Pharmaceuticals). It is mainly used to treat patients with chronic myelogenous leukemia (CML). With the continuous improvement of quality control standards for generic drugs, Qilu Pharmaceutical's version of nilotinib has passed the consistency evaluation by the China National Food and Drug Administration (NMPA), which means that its quality, efficacy and safety have basically reached the same standards as the original drug, providing domestic patients with a more cost-effective treatment option.

In terms of effectiveness, clinical studies of Qilu Pharmaceutical's version of nilotinib have shown that there is no significant difference between it and the original drug in terms of main molecular response rate, hematological response and inhibition of bone marrow cell transformation. Its active ingredients, dosage specifications, and bioequivalence are consistent with the original drug and comply with international generic drug standards. Therefore, in clinical applications, doctors can usually recommend generic drugs as an alternative based on the patient's financial status and treatment needs without affecting the efficacy.

In terms of safety, the Qilut version of nilotinib and the original drug need to pay attention to potential side effects, such as QT interval prolongation, elevated liver enzymes, blood sugar changes, etc. Since the excipients and production processes used in generic drugs may be slightly different, very few patients may have differences in tolerance or adverse reactions. But in general, domestic generic drugs that have passed consistency evaluation can show similar safety and tolerability to the original drugs in most patients.

In terms of price, the biggest advantage of Qilu Pharmaceutical’s version of nilotinib is its significant cost savings. Compared with original drugs that cost tens of thousands of yuan per box, the Qilu version is priced significantly lower and has been included in the national medical insurance catalog. Qualified patients can enjoy a large proportion of medical insurance reimbursement, which greatly reduces the burden of treatment. Taken together, Qilu Pharmaceutical's version of nilotinib has achieved a good balance between efficacy, safety and economy, and is currently a very practical and reliable medication choice for domestic CML patients.

Reference materials:https://www.drugs.com/